BAR1 LIFE Stock Australian S.E.

BD1

Pharmaceuticals

End-of-day quote Australian S.E. Other stock markets			5-day change	1st Jan Change
- ^AUD	-.--%		-.--%	-

06-25	Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%	MT
02-18	INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI

INOVIQ Ltd is an Australia-based biotechnology company developing diagnostics and therapeutics for cancer. The Company's commercialized products include EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The Company is also advancing clinical-stage diagnostics for the detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumors.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.2000AUD

Average target price

0.7000AUD

Spread / Average Target

+250.00%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	26.75M 18.9M 16.36M 15.29M 13.98M 26.34M 1.8B 179M 70.36M 902M 70.96M 69.41M 3B	P/E 2026 *	-4.75x	P/E 2027 *	-4.75x
Enterprise Value	26.75M 18.9M 16.36M 15.29M 13.98M 26.34M 1.8B 179M 70.36M 902M 70.96M 69.41M 3B	EV / Sales 2026 *	29.7x	EV / Sales 2027 *	19.1x
Free-Float	66.05%	Yield 2026 *	-	Yield 2027 *	-

06-25	Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%	MT
02-18	INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI
12-23	INOVIQ Appoints Chief Scientific Officer	MT
12-23	INOVIQ Limited Announces Management Changes, Effective January 12, 2026	CI
12-18	Inoviq says Peter Gunzburg elected to role of chairman	RE
11-27	Inoviq Ltd Elects Peter Gunzburg as Non-Executive Director	CI
11-27	Inoviq says chairman David Williams to step down at year-end	RE
17/10/25	INOVIQ Ltd Announces Appointment of Peter Gunzburg as A Non-Executive Director, Effective 20 October 2025	CI
13/10/25	Inoviq completes A$9.5 million placement	RE
09/10/25	Inoviq Ltd seeks trading halt	RE
26/09/25	INOVIQ Secures Worldwide License for Development, Commercialization of Ovarian Cancer Detection Biomarkers; Shares Jump 5%	MT
26/09/25	Inoviq licences worldwide rights to ovarian cancer biomarker IP from UniQuest	RE
22/08/25	INOVIQ Ltd Reports Earnings Results for the Full Year Ended June 30, 2025	CI

07/07/23	INOVIQ AND PROMEGA ANNOUNCE GLOBAL JOINT MARKETING AGREEMENT FOR EXO-NET EXOSOME ISOLATION AND NUCLEIC ACID PURIFICATION SOLUTIONS	AQ
27/07/22	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - June 2022	PU
29/04/22	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - March 2022	PU
06/04/22	INOVIQ : Updated Investor Presentation	PU
07/12/21	BARD1 Life Sciences : Application for quotation of securities - BD1	PU

Manager	Title	Age	Since
Leearne Hinch CEO	Chief Executive Officer	-	07/11/2016
Mark Edwards DFI	Director of Finance/CFO	-	02/11/2022
Rebecca Lim CTO	Chief Tech/Sci/R&D Officer	-	12/01/2026

Director	Title	Age	Since
Philip Powell BRD	Director/Board Member	67	18/06/2019
Robert Johnston BRD	Director/Board Member	-	18/06/2019
Geoff Cumming CHM	Chairman	-	28/07/2020

BAR1 LIFE Stock Australian S.E.

Stocks

BD1

Pharmaceuticals

Valuation: BAR1 LIFE

Latest news : BAR1 LIFE

Press Releases: BAR1 LIFE

Managers and Directors: BAR1 LIFE

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAR1 LIFE	-.--%	-.--%	-	-	19.89M
ELI LILLY AND COMPANY	-1.10%	+9.72%	+92.71%	+131.72%	1,098B
JOHNSON & JOHNSON	-0.80%	+2.48%	+50.30%	+50.27%	631B
ABBVIE INC.	+0.30%	+1.95%	+25.13%	+63.33%	438B
ROCHE HOLDING AG	-0.63%	+3.61%	+50.47%	+39.77%	368B
NOVARTIS AG	-0.73%	+1.73%	+32.01%	+39.63%	298B
ASTRAZENECA PLC	-0.86%	+1.12%	+7.58%	+7.63%	251B
AMGEN INC.	-0.76%	+6.40%	+45.57%	+58.09%	226B
NOVO NORDISK A/S	+0.29%	-0.42%	-5.05%	-50.64%	209B
GILEAD SCIENCES, INC.	+1.58%	-0.76%	+11.41%	+67.78%	165B
Average	-0.36%	+1,657.21%	+34.46%	+45.29%	409.37B
Weighted average by Cap.	-0.69%	+1,331.50%	+50.39%	+66.81%

	2026 *	2027 *
Net sales	900K 636K 550K 515K 470K 886K 60.64M 6.03M 2.37M 30.34M 2.39M 2.34M 101M	1.4M 989K 856K 800K 731K 1.38M 94.34M 9.39M 3.68M 47.19M 3.71M 3.63M 157M
Net income	-	-
Net Debt	-	-